Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells. When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia. When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)
Biomarker and diagnostic research for T lymphoblastic leukemia/lymphoma has been reported in the published literature.
7 clinical trials registered, 4 recruiting. Interventions under study include biologic therapy, drug therapy, other interventions, and procedural interventions. Pipeline includes 4 PHASE2, 2 PHASE1, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05620680](https://clinicaltrials.gov/study/NCT05620680) |
Data assembled from 3 of 12 sources · Last updated Oct 3, 2026, 5:31 PM UTC
Common questions about T lymphoblastic leukemia/lymphoma
CD7 CAR-T Cells in T-cell Lymphoma/Leukemia |
NA |
Shenzhen University General Hospital |
RECRUITING |
[NCT07072585](https://clinicaltrials.gov/study/NCT07072585) | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) | PHASE2 | Children's Oncology Group | NOT_YET_RECRUITING |
[NCT06712121](https://clinicaltrials.gov/study/NCT06712121) | Venetoclax and Decitabine in R/R T-ALL | PHASE2 | Seoul National University Hospital | RECRUITING |
[NCT07109518](https://clinicaltrials.gov/study/NCT07109518) | uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | PHASE1 | Institute of Hematology & Blood Diseases Hospital, China | UNKNOWN |
[NCT07153068](https://clinicaltrials.gov/study/NCT07153068) | SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | PHASE1 | Institute of Hematology & Blood Diseases Hospital, China | RECRUITING |
34 publications have been identified in PubMed for T lymphoblastic leukemia/lymphoma. Research spans Case Report / Case Series (24%), Clinical Trial Publication (21%), and Diagnostic / Biomarker (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 8 | 24% |
Clinical study results | 7 | 21% |
Testing and diagnosis research | 6 | 18% |
Laboratory research | 5 | 15% |
Research summaries | 3 | 9% |
Disease patterns and progression | 3 | 9% |
New treatment approaches | 2 | 6% |
Tang G (2026). [PMID: 41796805](https://pubmed.ncbi.nlm.nih.gov/41796805/). *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. [Diagnostic / Biomarker]
Yuan Y (2026). [PMID: 41673103](https://pubmed.ncbi.nlm.nih.gov/41673103/). *Scientific reports*. [Gene Therapy / Novel Therapeutics]
Oliveira K (2026). [PMID: 42199998](https://pubmed.ncbi.nlm.nih.gov/42199998/). *Case Rep Pathol*. [Case Report / Case Series]
Yao X (2026). [PMID: 40493083](https://pubmed.ncbi.nlm.nih.gov/40493083/). *European journal of nuclear medicine and molecular imaging*. [Case Report / Case Series]
Smith TH (2026). [PMID: 41242614](https://pubmed.ncbi.nlm.nih.gov/41242614/). *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. [Basic Science / Preclinical]
Yang Y (2025). [PMID: 41032135](https://pubmed.ncbi.nlm.nih.gov/41032135/). *Annals of hematology*. [Diagnostic / Biomarker]
Hughes AD (2025). [PMID: 39781622](https://pubmed.ncbi.nlm.nih.gov/39781622/). *Haematologica*. [Diagnostic / Biomarker]
Yang Y (2025). [PMID: 40856820](https://pubmed.ncbi.nlm.nih.gov/40856820/). *Annals of hematology*. [Clinical Trial Publication]
Lang Y (2025). [PMID: 40230292](https://pubmed.ncbi.nlm.nih.gov/40230292/). *Histology and histopathology*. [Diagnostic / Biomarker]
Maggard J (2025). [PMID: 40013536](https://pubmed.ncbi.nlm.nih.gov/40013536/). *Cytometry. Part B, Clinical cytometry*. [Review / Meta-Analysis]